Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies.
about
Safety of apixaban for venous thromboembolism prophylaxis: the evidence to dateApixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based reviewNon-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused ReviewThe Reversal of Direct Oral Anticoagulants in Animal Models.A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation--full speed ahead or proceed with caution?Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjectsReversal of novel oral anticoagulants in patients with major bleeding.Model-based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery.Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation.Interrupting anticoagulation in patients with nonvalvular atrial fibrillation.New options in anticoagulation for the prevention of venous thromboembolism and stroke.Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.Thromboprophylaxis with apixaban and the risk of pulmonary embolism in patients undergoing knee replacement surgeryStroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixabanEffect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients.Depression in patients with chronic hepatitis B and cirrhosis is closely associated with the severity of liver cirrhosis.The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants.The effect of a dual or a triple antithrombotic therapy with apixaban on thrombus formation in vivo and in an ex vivo perfusion chamber model: An open-label, controlled, sequential study.Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.Apixaban in patients with Atrial Fibrillation: A Systematic ReviewRecent developments in the use of oral anticoagulants.Novel factor Xa inhibitors: a patent review.Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.Treatment options for deep vein thrombosis.Apixaban in acute coronary syndromes.Blood coagulation factor Xa as an emerging drug target.Laboratory assessment of new anticoagulants.Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor.Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes.The role of apixaban for venous and arterial thromboembolic disease.Novel oral anticoagulants and their role in clinical practice.Apixaban: an oral direct factor-xa inhibitor.The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis.New anticoagulants in ischemic heart disease.Anticoagulant therapy for patients with ischaemic stroke.Advances in the diagnosis and treatment of acute pulmonary embolism.The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review.
P2860
Q26764874-47AC4830-D6A2-4C7E-88E1-AF960F0EE8E8Q26783455-DE588C4D-434C-4BEB-8477-0D248BB0CE15Q28081918-886505FF-F268-4BF2-8169-B64D27CBD107Q30491580-E0001E8A-571C-4E53-8D63-6DB7B0E1AAD9Q34109813-629E629D-607C-4051-A92A-F4C8F5F538EDQ34285711-B615FECE-E858-4209-8DFE-7D1B5011BA5AQ34326655-0F8EF81D-CAFA-4C4F-8FBD-3A885A2CF8E5Q34413003-5617E924-B8A3-4C84-A794-4A84F06009E8Q34627780-3BAAE63A-8D8D-4A5A-8BCB-F0A1B783E505Q34658856-DF11AB5E-6CD7-4FCC-9AFF-398444732C89Q34688742-F63667EB-F270-4C12-8327-AA1E9977053BQ34906214-6CAA3A75-D4AE-4ACC-BC8E-A61ECC794E04Q35557449-DF6FCE92-7DDE-4863-9803-22498B0BB46CQ36021499-8048A54F-286C-4E4D-AC67-515F2DC4F28BQ36241389-C1EA3426-FAE7-40DF-A540-6F4EE5DFF9DDQ36797336-415198DA-BDE7-42B9-8EF6-7BC0E0D9A41EQ36839479-F3FEC3E1-2EE2-4042-B54D-B259912D3748Q37001709-61465BCF-4A2F-40D1-A179-E6FFF95998FBQ37316352-AB1AC82B-21AB-4D7B-A792-BF4ACA272451Q37328158-FECEF471-CD87-4A42-B3DE-F45A4036A3A3Q37353441-FBBFCF6A-55EA-4B4D-BB76-28487554F879Q37369329-278E6755-E312-4A13-8200-FBB32B630A3DQ37495983-543A47DA-41FC-45B1-8E34-CE38ECF85B3DQ37528463-7597A9D3-3262-44CB-9393-0F18DC5468FCQ37594779-0C0CCBBF-605E-4BEF-A25D-B00A229A8B1BQ37653181-8054D1F9-2EC7-4B46-AF54-9313C01A8EDCQ37733553-D9AC0BA8-0CEB-4679-9B13-415CA5411B20Q37765608-0B6C7D18-B33D-4974-9716-B254157678C1Q37830708-A2E9D1CA-5327-4FE8-9E55-68020CC0ED68Q37834646-1AAEF352-8B27-48E8-B3D9-359F7D13BC6BQ37841256-DECAD873-016D-480B-B5E4-B7D6E6B971D2Q37850800-5F2392A3-53E8-402B-8D8C-04F11B5FC519Q37939851-BE7976FC-2282-4344-ADE1-E442322FCAE6Q37961824-7922D775-3B4E-4C8A-ACCC-50030A1D7228Q37987051-C86AA1B9-2062-4CD5-912B-79AF33CEC213Q37990316-F035F21B-3CBC-4EC0-B17B-D1817E549E1FQ38005012-76F33C50-31E8-4EFA-B9EF-3DF88406A797Q38008152-7A6D58B1-9F59-4C78-B42F-D4385D5C29A0Q38012449-D5F922E5-46BE-47C2-ACC2-ECA5EDBF00EAQ38015427-54AF64F6-636E-4107-8515-DE3E06976663
P2860
Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Apixaban, an oral, direct and ...... ic and antihemostatic studies.
@en
Apixaban, an oral, direct and ...... ic and antihemostatic studies.
@nl
type
label
Apixaban, an oral, direct and ...... ic and antihemostatic studies.
@en
Apixaban, an oral, direct and ...... ic and antihemostatic studies.
@nl
prefLabel
Apixaban, an oral, direct and ...... ic and antihemostatic studies.
@en
Apixaban, an oral, direct and ...... ic and antihemostatic studies.
@nl
P2093
P2860
P1476
Apixaban, an oral, direct and ...... ic and antihemostatic studies.
@en
P2093
J M Luettgen
R R Wexler
P2860
P304
P356
10.1111/J.1538-7836.2008.02939.X
P577
2008-02-25T00:00:00Z